IBDEI03B ; ; 19-NOV-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4010,1,5,0)
 ;;=5^DEMEN NOS W/O BEHV DSTRB
 ;;^UTILITY(U,$J,358.3,4010,2)
 ;;=^340607
 ;;^UTILITY(U,$J,358.3,4011,0)
 ;;=294.21^^23^231^10
 ;;^UTILITY(U,$J,358.3,4011,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4011,1,4,0)
 ;;=4^294.21
 ;;^UTILITY(U,$J,358.3,4011,1,5,0)
 ;;=5^DEMEN NOS W BEHAV DISTRB
 ;;^UTILITY(U,$J,358.3,4011,2)
 ;;=^340505
 ;;^UTILITY(U,$J,358.3,4012,0)
 ;;=294.8^^23^231^19
 ;;^UTILITY(U,$J,358.3,4012,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4012,1,4,0)
 ;;=4^294.8
 ;;^UTILITY(U,$J,358.3,4012,1,5,0)
 ;;=5^MENTAL DISOR NEC OTH DIS
 ;;^UTILITY(U,$J,358.3,4012,2)
 ;;=^31655
 ;;^UTILITY(U,$J,358.3,4013,0)
 ;;=V41.0^^24^232^19
 ;;^UTILITY(U,$J,358.3,4013,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4013,1,1,0)
 ;;=1^V41.0
 ;;^UTILITY(U,$J,358.3,4013,1,2,0)
 ;;=2^VISUALLY IMPAIRED
 ;;^UTILITY(U,$J,358.3,4013,2)
 ;;=^295427
 ;;^UTILITY(U,$J,358.3,4014,0)
 ;;=250.01^^24^232^14
 ;;^UTILITY(U,$J,358.3,4014,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4014,1,1,0)
 ;;=1^250.01
 ;;^UTILITY(U,$J,358.3,4014,1,2,0)
 ;;=2^IDDM
 ;;^UTILITY(U,$J,358.3,4014,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,4015,0)
 ;;=250.00^^24^232^16
 ;;^UTILITY(U,$J,358.3,4015,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4015,1,1,0)
 ;;=1^250.00
 ;;^UTILITY(U,$J,358.3,4015,1,2,0)
 ;;=2^NIDDM
 ;;^UTILITY(U,$J,358.3,4015,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,4016,0)
 ;;=401.0^^24^232^11
 ;;^UTILITY(U,$J,358.3,4016,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4016,1,1,0)
 ;;=1^401.0
 ;;^UTILITY(U,$J,358.3,4016,1,2,0)
 ;;=2^HYPERTENSION MALIGNANT
 ;;^UTILITY(U,$J,358.3,4016,2)
 ;;=^73505
 ;;^UTILITY(U,$J,358.3,4017,0)
 ;;=796.0^^24^232^2
 ;;^UTILITY(U,$J,358.3,4017,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4017,1,1,0)
 ;;=1^796.0
 ;;^UTILITY(U,$J,358.3,4017,1,2,0)
 ;;=2^ABNORMAL LAB FINDINGS
 ;;^UTILITY(U,$J,358.3,4017,2)
 ;;=^273463
 ;;^UTILITY(U,$J,358.3,4018,0)
 ;;=305.1^^24^232^17
 ;;^UTILITY(U,$J,358.3,4018,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4018,1,1,0)
 ;;=1^305.1
 ;;^UTILITY(U,$J,358.3,4018,1,2,0)
 ;;=2^SMOKER
 ;;^UTILITY(U,$J,358.3,4018,2)
 ;;=^119899
 ;;^UTILITY(U,$J,358.3,4019,0)
 ;;=272.2^^24^232^15
 ;;^UTILITY(U,$J,358.3,4019,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4019,1,1,0)
 ;;=1^272.2
 ;;^UTILITY(U,$J,358.3,4019,1,2,0)
 ;;=2^MIXED HYPERLIPIDEMIA
 ;;^UTILITY(U,$J,358.3,4019,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,4020,0)
 ;;=401.9^^24^232^12
 ;;^UTILITY(U,$J,358.3,4020,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4020,1,1,0)
 ;;=1^401.9
 ;;^UTILITY(U,$J,358.3,4020,1,2,0)
 ;;=2^HYPERTENSION, ESSENTIAL
 ;;^UTILITY(U,$J,358.3,4020,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,4021,0)
 ;;=286.59^^24^232^9
 ;;^UTILITY(U,$J,358.3,4021,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4021,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,4021,1,2,0)
 ;;=2^HEM DISORDER D/T CIRC ANTICOAG
 ;;^UTILITY(U,$J,358.3,4021,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,4022,0)
 ;;=401.1^^24^232^13
 ;;^UTILITY(U,$J,358.3,4022,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4022,1,1,0)
 ;;=1^401.1
 ;;^UTILITY(U,$J,358.3,4022,1,2,0)
 ;;=2^HYPERTENSION,BENIGN
 ;;^UTILITY(U,$J,358.3,4022,2)
 ;;=^269591
 ;;^UTILITY(U,$J,358.3,4023,0)
 ;;=796.4^^24^232^1
 ;;^UTILITY(U,$J,358.3,4023,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4023,1,1,0)
 ;;=1^796.4
 ;;^UTILITY(U,$J,358.3,4023,1,2,0)
 ;;=2^ABNORMAL CLINICAL FINDINGS
 ;;^UTILITY(U,$J,358.3,4023,2)
 ;;=^273466
 ;;^UTILITY(U,$J,358.3,4024,0)
 ;;=250.80^^24^232^8
 ;;^UTILITY(U,$J,358.3,4024,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4024,1,1,0)
 ;;=1^250.80
 ;;^UTILITY(U,$J,358.3,4024,1,2,0)
 ;;=2^DIABETES TYPE II w/ SPEC MANIF
 ;;^UTILITY(U,$J,358.3,4024,2)
 ;;=^331811
 ;;^UTILITY(U,$J,358.3,4025,0)
 ;;=250.81^^24^232^7
 ;;^UTILITY(U,$J,358.3,4025,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4025,1,1,0)
 ;;=1^250.81
 ;;^UTILITY(U,$J,358.3,4025,1,2,0)
 ;;=2^DIABETES TYPE I w/ SPEC MANIF
 ;;^UTILITY(U,$J,358.3,4025,2)
 ;;=^331812
 ;;^UTILITY(U,$J,358.3,4026,0)
 ;;=368.8^^24^232^18
 ;;^UTILITY(U,$J,358.3,4026,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4026,1,1,0)
 ;;=1^368.8
 ;;^UTILITY(U,$J,358.3,4026,1,2,0)
 ;;=2^VISUAL DISTURBANCES NEC
 ;;^UTILITY(U,$J,358.3,4026,2)
 ;;=^88172
 ;;^UTILITY(U,$J,358.3,4027,0)
 ;;=303.90^^24^232^6
 ;;^UTILITY(U,$J,358.3,4027,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4027,1,1,0)
 ;;=1^303.90
 ;;^UTILITY(U,$J,358.3,4027,1,2,0)
 ;;=2^ALCOHOL DEP NEC/NOS,UNSPEC
 ;;^UTILITY(U,$J,358.3,4027,2)
 ;;=^4648
 ;;^UTILITY(U,$J,358.3,4028,0)
 ;;=303.91^^24^232^3
 ;;^UTILITY(U,$J,358.3,4028,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4028,1,1,0)
 ;;=1^303.91
 ;;^UTILITY(U,$J,358.3,4028,1,2,0)
 ;;=2^ALCOHOL DEP NEC/NOS,CONTINUOUS
 ;;^UTILITY(U,$J,358.3,4028,2)
 ;;=^268188
 ;;^UTILITY(U,$J,358.3,4029,0)
 ;;=303.92^^24^232^4
 ;;^UTILITY(U,$J,358.3,4029,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4029,1,1,0)
 ;;=1^303.92
 ;;^UTILITY(U,$J,358.3,4029,1,2,0)
 ;;=2^ALCOHOL DEP NEC/NOS,EPISODIC
 ;;^UTILITY(U,$J,358.3,4029,2)
 ;;=^268189
 ;;^UTILITY(U,$J,358.3,4030,0)
 ;;=303.93^^24^232^5
 ;;^UTILITY(U,$J,358.3,4030,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4030,1,1,0)
 ;;=1^303.93
 ;;^UTILITY(U,$J,358.3,4030,1,2,0)
 ;;=2^ALCOHOL DEP NEC/NOS,IN REMISSION
 ;;^UTILITY(U,$J,358.3,4030,2)
 ;;=^268190
 ;;^UTILITY(U,$J,358.3,4031,0)
 ;;=V11.3^^24^232^10
 ;;^UTILITY(U,$J,358.3,4031,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4031,1,1,0)
 ;;=1^V11.3
 ;;^UTILITY(U,$J,358.3,4031,1,2,0)
 ;;=2^HX OF ALCOHOLISM
 ;;^UTILITY(U,$J,358.3,4031,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,4032,0)
 ;;=V68.1^^24^233^16
 ;;^UTILITY(U,$J,358.3,4032,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4032,1,1,0)
 ;;=1^V68.1
 ;;^UTILITY(U,$J,358.3,4032,1,2,0)
 ;;=2^MEDICATION RENEWAL
 ;;^UTILITY(U,$J,358.3,4032,2)
 ;;=^295585
 ;;^UTILITY(U,$J,358.3,4033,0)
 ;;=V65.49^^24^233^15
 ;;^UTILITY(U,$J,358.3,4033,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4033,1,1,0)
 ;;=1^V65.49
 ;;^UTILITY(U,$J,358.3,4033,1,2,0)
 ;;=2^MEDICATION COUNSELING
 ;;^UTILITY(U,$J,358.3,4033,2)
 ;;=^303471
 ;;^UTILITY(U,$J,358.3,4034,0)
 ;;=250.92^^24^233^4
 ;;^UTILITY(U,$J,358.3,4034,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4034,1,1,0)
 ;;=1^250.92
 ;;^UTILITY(U,$J,358.3,4034,1,2,0)
 ;;=2^DIABETES W/UNSPEC COMP TYPE II
 ;;^UTILITY(U,$J,358.3,4034,2)
 ;;=^295722
 ;;^UTILITY(U,$J,358.3,4035,0)
 ;;=250.00^^24^233^3
 ;;^UTILITY(U,$J,358.3,4035,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4035,1,1,0)
 ;;=1^250.00
 ;;^UTILITY(U,$J,358.3,4035,1,2,0)
 ;;=2^DIABETES II
 ;;^UTILITY(U,$J,358.3,4035,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,4036,0)
 ;;=V67.51^^24^233^6
 ;;^UTILITY(U,$J,358.3,4036,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4036,1,1,0)
 ;;=1^V67.51
 ;;^UTILITY(U,$J,358.3,4036,1,2,0)
 ;;=2^HI-RISK RX F/U EXAM,NEC
 ;;^UTILITY(U,$J,358.3,4036,2)
 ;;=^295577
 ;;^UTILITY(U,$J,358.3,4037,0)
 ;;=V14.9^^24^233^9
 ;;^UTILITY(U,$J,358.3,4037,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4037,1,1,0)
 ;;=1^V14.9
 ;;^UTILITY(U,$J,358.3,4037,1,2,0)
 ;;=2^HX-DRUG ALLERGY NOS
 ;;^UTILITY(U,$J,358.3,4037,2)
 ;;=^295282
 ;;^UTILITY(U,$J,358.3,4038,0)
 ;;=V15.81^^24^233^8
 ;;^UTILITY(U,$J,358.3,4038,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4038,1,1,0)
 ;;=1^V15.81
 ;;^UTILITY(U,$J,358.3,4038,1,2,0)
 ;;=2^HX OF PAST NONCOMPLIANCE
 ;;^UTILITY(U,$J,358.3,4038,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,4039,0)
 ;;=401.9^^24^233^12
 ;;^UTILITY(U,$J,358.3,4039,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4039,1,1,0)
 ;;=1^401.9
 ;;^UTILITY(U,$J,358.3,4039,1,2,0)
 ;;=2^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,4039,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,4040,0)
 ;;=V58.61^^24^233^13
 ;;^UTILITY(U,$J,358.3,4040,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4040,1,1,0)
 ;;=1^V58.61
 ;;^UTILITY(U,$J,358.3,4040,1,2,0)
 ;;=2^L/T (CURRENT) USE - ANTICOAG
 ;;^UTILITY(U,$J,358.3,4040,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,4041,0)
 ;;=V65.19^^24^233^17
 ;;^UTILITY(U,$J,358.3,4041,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4041,1,1,0)
 ;;=1^V65.19
 ;;^UTILITY(U,$J,358.3,4041,1,2,0)
 ;;=2^PERSON CONSULT FOR ANOTH
 ;;^UTILITY(U,$J,358.3,4041,2)
 ;;=^329985
 ;;^UTILITY(U,$J,358.3,4042,0)
 ;;=272.4^^24^233^11
 ;;^UTILITY(U,$J,358.3,4042,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4042,1,1,0)
 ;;=1^272.4
 ;;^UTILITY(U,$J,358.3,4042,1,2,0)
 ;;=2^HYPERLIPIDEMIA NOS
 ;;^UTILITY(U,$J,358.3,4042,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,4043,0)
 ;;=285.29^^24^233^1
 ;;^UTILITY(U,$J,358.3,4043,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4043,1,1,0)
 ;;=1^285.29
 ;;^UTILITY(U,$J,358.3,4043,1,2,0)
 ;;=2^ANEMIA IN CHRONIC ILLNESS
 ;;^UTILITY(U,$J,358.3,4043,2)
 ;;=^334228
 ;;^UTILITY(U,$J,358.3,4044,0)
 ;;=585.6^^24^233^5
 ;;^UTILITY(U,$J,358.3,4044,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4044,1,1,0)
 ;;=1^585.6
 ;;^UTILITY(U,$J,358.3,4044,1,2,0)
 ;;=2^ESRD
 ;;^UTILITY(U,$J,358.3,4044,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,4045,0)
 ;;=V58.69^^24^233^14
 ;;^UTILITY(U,$J,358.3,4045,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4045,1,1,0)
 ;;=1^V58.69
 ;;^UTILITY(U,$J,358.3,4045,1,2,0)
 ;;=2^L/T CURRENT USE OF OTHER MEDS
 ;;^UTILITY(U,$J,358.3,4045,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,4046,0)
 ;;=V58.61^^24^234^14
 ;;^UTILITY(U,$J,358.3,4046,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4046,1,1,0)
 ;;=1^V58.61
 ;;^UTILITY(U,$J,358.3,4046,1,2,0)
 ;;=2^L/T (CURRENT) USE - ANTICOAG
 ;;^UTILITY(U,$J,358.3,4046,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,4047,0)
 ;;=427.31^^24^234^1
 ;;^UTILITY(U,$J,358.3,4047,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4047,1,1,0)
 ;;=1^427.31
 ;;^UTILITY(U,$J,358.3,4047,1,2,0)
 ;;=2^ATRIAL FIBRILLATION
 ;;^UTILITY(U,$J,358.3,4047,2)
 ;;=^11378
 ;;^UTILITY(U,$J,358.3,4048,0)
 ;;=427.32^^24^234^2
 ;;^UTILITY(U,$J,358.3,4048,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4048,1,1,0)
 ;;=1^427.32
 ;;^UTILITY(U,$J,358.3,4048,1,2,0)
 ;;=2^ATRIAL FLUTTER
